Basic Information
RNALocate ID: | RLID:11001925 |
RNA Symbol: | hsa-miR-150-5p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-150-5p |
RNA ID: | miRBase:MIMAT0000451 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 22211110 |
Tissue/Cell Line: | Breast milk |
Method: | Next-generation RNA sequencing |
The expression profile of selected miRNAs in breast milk exosomes. Originally published in Int J Biol Sci. Zhou Q, et al, 2012. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | Distribution and characterization of miRNAs in breast milk exosomes. (A) Distribution of pre-miRNAs. Out of 1,424 pre-miRNAs deposited in miRBase 17.0 (blue circle), 87 (6.11%) pre-miRNAs have been designated as immune-related pre-miRNAs based on annotation in the Pathway Central database (SABiosciences, MD, USA). Immune-related pre-miRNAs (59 of 452, 13.05%) are enriched in breast milk exosomes (red circle). χ2 test: Number of immune-related miRNAs and others detected in breast milk exosomes compared with the total entries in miRBase 17.0. (B) Top ten most highly expressed unique miRNAs. Plot of the unique miRNAs (starting from the miRNA with the highest counts, x-axis) versus their cumulative % of the total counts from 602 unique miRNAs detected in breast milk exosomes for each small RNA library. Values are means ± s.d. The dashed horizontal line at 62.3% represents the level of the top ten unique miRNAs and the % of individual miRNAs is marked by the gray line. (C-E) The expression profile of selected miRNAs in breast milk exosomes. (C) 59 immune-related pre-miRNAs; (D) miR-17-92 cluster and paralogous clusters, and (E) ten well-characterized tissue-specific pre-miRNAs. Data are collected from Figure 2. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001836 | Lysosome | HeLa cells|MCF-7 cells | 29784380 |
RLID:01001837 | Mitochondrion | Human cervical cancer cell line (HeLa)|Breast cancer cell line (MCF-7) | 29784380 |
RLID:11001921 | Exosome | Peripheral blood | 31746410 |
RLID:11001922 | Exosome | Primary ovarian tumor cells|Serum | 18589210 |
RLID:11001923 | Exosome | Saliva | 19627513 |
RLID:11001924 | Exosome | B cell line (Raji)|Jurkat-derived T cell line (J77cl20) | 21505438 |
RLID:11001926 | Exosome | Brain tissue | 23382797 |
RLID:11001927 | Exosome | Plasma | 23663360 |
RLID:11001928 | Exosome | Serum | 25135963 |
RLID:11001929 | Extracellular Vesicle | Plasma | 28588009 |
RLID:11001930 | Extracellular vesicle | HEK-293T cells | 22849433 |
RLID:11001931 | Microvesicle | Follicular fluid | 23666971 |
RLID-D:11000099 | Exosome | Blood|B lymphoblastoid cells|Colon tissue|Endothelial cells|Lymphoma tissue|Mast cells | |
RLID-D:11000379 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-150-5p | Diffuse large b cell lymphoma | MNDR-E-MI-16569 |
MNDR | hsa-miR-150-5p | Splenic marginal zone lymphoma | MNDR-E-MI-16570 |
MNDR | hsa-miR-150-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-16571 |
MNDR | hsa-miR-150-5p | Large cell neuroendocrine cancer | MNDR-E-MI-16572 |
MNDR | hsa-miR-150-5p | Medulloblastoma | MNDR-E-MI-16573 |
MNDR | hsa-miR-150-5p | B cell lymphoma of malt type | MNDR-E-MI-16574 |
MNDR | hsa-miR-150-5p | Small intestinal neuroendocrine tumor | MNDR-E-MI-16575 |
MNDR | hsa-miR-150-5p | Lymphoma | MNDR-E-MI-16576 |
MNDR | hsa-miR-150-5p | Lymphoma non-hodgkin | MNDR-E-MI-16577 |
MNDR | hsa-miR-150-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-16578 |
MNDR | hsa-miR-150-5p | Her2-receptor positive breast cancer | MNDR-E-MI-16579 |
MNDR | hsa-miR-150-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-16580 |
MNDR | hsa-miR-150-5p | B cell acute lymphoblastic leukemia | MNDR-E-MI-16581 |
MNDR | hsa-miR-150-5p | Small intestine cancer | MNDR-E-MI-16582 |
MNDR | hsa-miR-150-5p | Prostate cancer | MNDR-E-MI-16583 |
MNDR | hsa-miR-150-5p | Chronic lymphocytic leukemia | MNDR-E-MI-16584 |
MNDR | hsa-miR-150-5p | Gastric cancer | MNDR-E-MI-16585 |
MNDR | hsa-miR-150-5p | Gastric lymphoma | MNDR-E-MI-16586 |
MNDR | hsa-miR-150-5p | Alzheimer disease | MNDR-E-MI-16587 |
MNDR | hsa-miR-150-5p | Intracranial aneurysm | MNDR-E-MI-16588 |
MNDR | hsa-miR-150-5p | Osteoporosis | MNDR-E-MI-16589 |
MNDR | hsa-miR-150-5p | Dysautonomia familial | MNDR-E-MI-16590 |
MNDR | hsa-miR-150-5p | Head and neck cancer | MNDR-E-MI-16591 |
MNDR | hsa-miR-150-5p | Primary biliary cirrhosis | MNDR-E-MI-16592 |
MNDR | hsa-miR-150-5p | Leukemia | MNDR-E-MI-16593 |
MNDR | hsa-miR-150-5p | Huntington disease | MNDR-E-MI-16594 |
MNDR | hsa-miR-150-5p | Chorea | MNDR-E-MI-16595 |
MNDR | hsa-miR-150-5p | Cardiovascular disease | MNDR-E-MI-16596 |
MNDR | hsa-miR-150-5p | Uterine fibroid | MNDR-E-MI-16597 |
MNDR | hsa-miR-150-5p | Lung cancer | MNDR-E-MI-16598 |
MNDR | hsa-miR-150-5p | Giant cell arteritis | MNDR-E-MI-16599 |
MNDR | hsa-miR-150-5p | Kawasaki disease | MNDR-E-MI-16600 |
MNDR | hsa-miR-150-5p | Down syndrome | MNDR-E-MI-16601 |
MNDR | hsa-miR-150-5p | Parkinson disease | MNDR-E-MI-16602 |
MNDR | hsa-miR-150-5p | Basal-like breast cancer | MNDR-E-MI-16603 |
MNDR | hsa-miR-150-5p | Squamous cell carcinoma | MNDR-E-MI-16604 |
MNDR | hsa-miR-150-5p | Thyroid cancer | MNDR-E-MI-16605 |
MNDR | hsa-miR-150-5p | Pituitary neoplasms | MNDR-E-MI-16606 |
MNDR | hsa-miR-150-5p | Pancreatic cancer | MNDR-E-MI-16607 |
MNDR | hsa-miR-150-5p | Melanoma | MNDR-E-MI-16608 |
MNDR | hsa-miR-150-5p | Rectum adenocarcinoma | MNDR-E-MI-16609 |
MNDR | hsa-miR-150-5p | Nephroblastoma | MNDR-E-MI-16610 |
MNDR | hsa-miR-150-5p | Colon cancer | MNDR-E-MI-16611 |
MNDR | hsa-miR-150-5p | Colon adenocarcinoma | MNDR-E-MI-16612 |
MNDR | hsa-miR-150-5p | Multiple sclerosis | MNDR-E-MI-16613 |
MNDR | hsa-miR-150-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-16614 |
MNDR | hsa-miR-150-5p | Familial ovarian cancer | MNDR-E-MI-16615 |
MNDR | hsa-miR-150-5p | Kidney cancer | MNDR-E-MI-16616 |
MNDR | hsa-miR-150-5p | Carcinoma ductal breast | MNDR-E-MI-16617 |
MNDR | hsa-miR-150-5p | Glioblastoma | MNDR-E-MI-16618 |
MNDR | hsa-miR-150-5p | Glioma | MNDR-E-MI-16619 |
MNDR | hsa-miR-150-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-16620 |
MNDR | hsa-miR-150-5p | Osteosarcoma | MNDR-E-MI-16621 |
MNDR | hsa-miR-150-5p | Inclusion body myositis | MNDR-E-MI-16622 |
MNDR | hsa-miR-150-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-16623 |
MNDR | hsa-miR-150-5p | Liver cancer | MNDR-E-MI-16624 |
MNDR | hsa-miR-150-5p | Uterine cancer | MNDR-E-MI-16625 |
MNDR | hsa-miR-150-5p | Gastric adenocarcinoma | MNDR-E-MI-16626 |
MNDR | hsa-miR-150-5p | Bone-invasive pituitary adenoma | MNDR-E-MI-16627 |
MNDR | hsa-miR-150-5p | Lung squamous cell carcinoma | MNDR-E-MI-16628 |
MNDR | hsa-miR-150-5p | Non-small cell lung cancer | MNDR-E-MI-16629 |
MNDR | hsa-miR-150-5p | Lung adenocarcinoma | MNDR-E-MI-16630 |
MNDR | hsa-miR-150-5p | Adrenocortical carcinoma | MNDR-E-MI-16631 |
MNDR | hsa-miR-150-5p | Thyroid carcinoma | MNDR-E-MI-16632 |
MNDR | hsa-miR-150-5p | Papillary thyroid carcinoma | MNDR-E-MI-16633 |
MNDR | hsa-miR-150-5p | Bladder urothelial carcinoma | MNDR-E-MI-16634 |
MNDR | hsa-miR-150-5p | Pancreatic adenocarcinoma | MNDR-E-MI-16635 |
MNDR | hsa-miR-150-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-16636 |
MNDR | hsa-miR-150-5p | Carcinoma renal cell | MNDR-E-MI-16637 |
MNDR | hsa-miR-150-5p | Papillary renal cell carcinoma | MNDR-E-MI-16638 |
MNDR | hsa-miR-150-5p | Renal clear cell carcinoma | MNDR-E-MI-16639 |
MNDR | hsa-miR-150-5p | Biliary tract cancer | MNDR-E-MI-16640 |
MNDR | hsa-miR-150-5p | Cholangiocarcinoma | MNDR-E-MI-16641 |
MNDR | hsa-miR-150-5p | Pancreatitis | MNDR-E-MI-16642 |
MNDR | hsa-miR-150-5p | Esophageal cancer | MNDR-E-MI-16643 |
MNDR | hsa-miR-150-5p | HIV | MNDR-E-MI-16644 |
MNDR | hsa-miR-150-5p | Lung small cell carcinoma | MNDR-E-MI-16645 |
MNDR | hsa-miR-150-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-16646 |
MNDR | hsa-miR-150-5p | Testicular germ cell cancer | MNDR-E-MI-16647 |
MNDR | hsa-miR-150-5p | T acute lymphoblastic leukemia | MNDR-E-MI-16648 |
MNDR | hsa-miR-150-5p | Acute t cell leukemia | MNDR-E-MI-16649 |
MNDR | hsa-miR-150-5p | Heart failure | MNDR-E-MI-16650 |
MNDR | hsa-miR-150-5p | Adenoma | MNDR-E-MI-16651 |
MNDR | hsa-miR-150-5p | Breast invasive carcinoma | MNDR-E-MI-16652 |
MNDR | hsa-miR-150-5p | Early hepatocellular carcinoma | MNDR-E-MI-16653 |
MNDR | hsa-miR-150-5p | Familiar ovarian carcinoma | MNDR-E-MI-16654 |
MNDR | hsa-miR-150-5p | B-cell lymphoma | MNDR-E-MI-16655 |
MNDR | hsa-miR-150-5p | Rheumatoid arthritis | MNDR-E-MI-16656 |
MNDR | hsa-miR-150-5p | T-cell leukemia | MNDR-E-MI-16657 |
MNDR | hsa-miR-150-5p | Retinoblastoma | MNDR-E-MI-16658 |
MNDR | hsa-miR-150-5p | Neuroblastoma | MNDR-E-MI-16659 |
MNDR | hsa-miR-150-5p | Periodontitis | MNDR-E-MI-16660 |
MNDR | hsa-miR-150-5p | Hodgkin lymphoma | MNDR-E-MI-16661 |
MNDR | hsa-miR-150-5p | Burkitt lymphoma | MNDR-E-MI-16662 |
MNDR | hsa-miR-150-5p | Skin cutaneous melanoma | MNDR-E-MI-16663 |
MNDR | hsa-miR-150-5p | Skin melanoma | MNDR-E-MI-16664 |
MNDR | hsa-miR-150-5p | Systemic lupus erythematosus | MNDR-E-MI-16665 |
MNDR | hsa-miR-150-5p | Acute myelogenous leukemia | MNDR-E-MI-16666 |
MNDR | hsa-miR-150-5p | Colorectal cancer | MNDR-E-MI-16667 |
MNDR | hsa-miR-150-5p | Nasopharynx carcinoma | MNDR-E-MI-16668 |
MNDR | hsa-miR-150-5p | Acute myocardial infarction | MNDR-E-MI-16669 |
MNDR | hsa-miR-150-5p | Multiple myeloma | MNDR-E-MI-16670 |
MNDR | hsa-miR-150-5p | Ovarian epithelial cancer | MNDR-E-MI-16671 |
MNDR | hsa-miR-150-5p | Esophageal squamous cell carcinoma | MNDR-E-MI-16672 |
MNDR | hsa-miR-150-5p | Ependymoma | MNDR-E-MI-16673 |
MNDR | hsa-miR-150-5p | Cardiomegaly | MNDR-E-MI-16674 |
MNDR | hsa-miR-150-5p | Infection | MNDR-E-MI-16675 |
MNDR | hsa-miR-150-5p | Nasopharyngeal cancer | MNDR-E-MI-16676 |
MNDR | hsa-miR-150-5p | Sleep deprivation | MNDR-E-MI-16677 |
MNDR | hsa-miR-150-5p | Wounds and injuries | MNDR-E-MI-16678 |
MNDR | hsa-miR-150-5p | Epstein-barr virus infections | MNDR-E-MI-16679 |
MNDR | hsa-miR-150-5p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-16680 |
MNDR | hsa-miR-150-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-16681 |
MNDR | hsa-miR-150-5p | Pituitary acth hypersecretion | MNDR-E-MI-16682 |
MNDR | hsa-miR-150-5p | Stroke lacunar | MNDR-E-MI-16683 |
MNDR | hsa-miR-150-5p | Duke A | MNDR-E-MI-16684 |
MNDR | hsa-miR-150-5p | Tubulovillous adenoma | MNDR-E-MI-16685 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ADIPOR2 | Homo sapiens | RR00047795 |
TOP